表紙
市場調査レポート

カンジダ症:パイプライン分析

Candidiasis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192515
出版日 ページ情報 英文 151 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
カンジダ症:パイプライン分析 Candidiasis - Pipeline Review, H2 2016
出版日: 2016年08月10日 ページ情報: 英文 151 Pages
概要

カンジダ症は、主にカンジダアルビカンスという種類のカンジダ属による感染によって引き起こされます。皮膚のカンジダ感染症では、特徴がはっきりした紅斑が見られ、皮膚のかゆみ、多くの場合は体液漏出があります。かさぶた、膿疱が見られることもあります。通常、鼠径部・臀部の内側などに見られ、胸の谷間、足指の間、手指の間、臍帯などにも見られます。治療には、抗真菌薬などが含まれます。

当レポートでは、カンジダ症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

カンジダ症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 未確認段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Amplyx Pharmaceuticals, Inc.
  • Bakker Medical Srl
  • Biomar Microbial Technologies
  • Cellceutix Corporation
  • Cidara Therapeutics, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • General Biologicals Corporation
  • Grupo Ferrer Internacional, S.A.
  • Hsiri Therapeutics, LLC
  • Nanomerics Ltd
  • Novabiotics Limited
  • NovaDigm Therapeutics, Inc.
  • Onxeo SA
  • Panacela Labs, Inc.
  • Scynexis, Inc.
  • Sealife PHARMA GMBH
  • TGV-Laboratories
  • Viamet Pharmaceuticals, Inc.
  • Wellstat Vaccines, LLC

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • 61894700
  • AC-17
  • amphotericin b
  • amphotericin B
  • amphotericin B
  • APX-001
  • arasertaconazole
  • Candida vaccine
  • candidiasis vaccine
  • CD-101
  • CTIX-1502
  • DWP-06081
  • Forazoline A
  • KSL-W
  • MH-010
  • miconazole nitrate
  • Monoclonal Antibodies to Target Fba for Candidiasis
  • mutanobactins
  • Myc-102
  • NDV-3
  • NDV-3A
  • NP-339
  • obliquumol
  • PAC-113
  • pegylated amphotericin B
  • PMX-1408
  • PMX-1570
  • PMX-1576
  • PMX-1591
  • PMX-1625
  • PMX-519
  • PMX-70004
  • Prof-002
  • 口腔咽頭カンジダ症用組換型ペプチド
  • SCY-078
  • SLP-0901
  • SLP-0904
  • 細菌性膣炎・カンジダ症用小分子
  • 全身性カンジダ症用小分子
  • アスペルギルス症・カンジダ症用小分子
  • カンジダ症用小分子
  • 真菌感染症用小分子
  • 多剤耐性細菌感染症用合成ペプチドSynthetic
  • VT-1161
  • XELRYX-3

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8343IDB

Summary

Global Markets Direct's, 'Candidiasis - Pipeline Review, H2 2016', provides an overview of the Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Candidiasis
  • The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects
  • The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Candidiasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Candidiasis Overview
  • Therapeutics Development
    • Pipeline Products for Candidiasis - Overview
    • Pipeline Products for Candidiasis - Comparative Analysis
  • Candidiasis - Therapeutics under Development by Companies
  • Candidiasis - Therapeutics under Investigation by Universities/Institutes
  • Candidiasis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Candidiasis - Products under Development by Companies
  • Candidiasis - Products under Investigation by Universities/Institutes
  • Candidiasis - Companies Involved in Therapeutics Development
    • Amplyx Pharmaceuticals, Inc.
    • Bakker Medical Srl
    • Biomar Microbial Technologies
    • Biosergen AS
    • Cellceutix Corporation
    • Cidara Therapeutics, Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Dermala Inc
    • General Biologicals Corporation
    • Grupo Ferrer Internacional, S.A.
    • Hsiri Therapeutics, LLC
    • iCo Therapeutics Inc.
    • Matinas BioPharma Holdings, Inc.
    • Nanomerics Ltd
    • Novabiotics Limited
    • NovaDigm Therapeutics, Inc.
    • Onxeo SA
    • Scynexis, Inc.
    • Sealife PHARMA GMBH
    • TGV-Laboratories
    • Viamet Pharmaceuticals, Inc.
    • Wellstat Vaccines, LLC
  • Candidiasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (clotrimazole + diclofenac sodium) - Drug Profile
    • (clotrimazole + diclofenac sodium) 1 - Drug Profile
    • 61894700 - Drug Profile
    • AC-17 - Drug Profile
    • amphotericin B - Drug Profile
    • amphotericin B - Drug Profile
    • amphotericin B - Drug Profile
    • Antibody to Target Ece1 for Candidiasis - Drug Profile
    • APX-001 - Drug Profile
    • arasertaconazole - Drug Profile
    • BSG-005 - Drug Profile
    • candidiasis vaccine - Drug Profile
    • CD-101 - Drug Profile
    • Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
    • CTIX-1502 - Drug Profile
    • Drug for Candidiasis - Drug Profile
    • DWP-06081 - Drug Profile
    • Forazoline A - Drug Profile
    • iCo-010 - Drug Profile
    • KSL-W - Drug Profile
    • MH-010 - Drug Profile
    • miconazole nitrate - Drug Profile
    • Monoclonal Antibodies for Candidiasis - Drug Profile
    • Monoclonal Antibody for Candidiasis - Drug Profile
    • Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile
    • Monoclonal Antibody to Inhibit the Beta-Glucan for Fungal Infections - Drug Profile
    • mutanobactins - Drug Profile
    • Myc-102 - Drug Profile
    • NDV-3 - Drug Profile
    • NDV-3A - Drug Profile
    • NP-339 - Drug Profile
    • obliquumol - Drug Profile
    • Occidiofungin - Drug Profile
    • PAC-113 - Drug Profile
    • PMX-1408 - Drug Profile
    • PMX-1570 - Drug Profile
    • PMX-1576 - Drug Profile
    • PMX-1591 - Drug Profile
    • PMX-1625 - Drug Profile
    • PMX-519 - Drug Profile
    • PMX-70004 - Drug Profile
    • Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile
    • SCY-078 - Drug Profile
    • SLP-0901 - Drug Profile
    • SLP-0904 - Drug Profile
    • Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
    • Small Molecule for Fungal Infections - Drug Profile
    • Small Molecules for Aspergillosis and Candidiasis - Drug Profile
    • Small Molecules for Candidiasis - Drug Profile
    • Small Molecules for Candidiasis - Drug Profile
    • Small Molecules for Candidiasis - Drug Profile
    • Small Molecules for Fungal Infections - Drug Profile
    • Small Molecules for Fungal Infections - Drug Profile
    • Small Molecules for Systemic Candidiasis - Drug Profile
    • Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile
    • Synthetic Peptides for Candidiasis - Drug Profile
    • Synthetic Peptides for Infections Diseases and Oncology - Drug Profile
    • TOL-463 - Drug Profile
    • Vaccine for Fungal Infections - Drug Profile
    • Vaccine to Target Ece1 for Candidiasis - Drug Profile
    • VT-1161 - Drug Profile
  • Candidiasis - Dormant Projects
  • Candidiasis - Discontinued Products
  • Candidiasis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Candidiasis, H2 2016
  • Number of Products under Development for Candidiasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Candidiasis - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016
  • Candidiasis - Pipeline by Bakker Medical Srl, H2 2016
  • Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2016
  • Candidiasis - Pipeline by Biosergen AS, H2 2016
  • Candidiasis - Pipeline by Cellceutix Corporation, H2 2016
  • Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016
  • Candidiasis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Candidiasis - Pipeline by Dermala Inc, H2 2016
  • Candidiasis - Pipeline by General Biologicals Corporation, H2 2016
  • Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
  • Candidiasis - Pipeline by Hsiri Therapeutics, LLC, H2 2016
  • Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2016
  • Candidiasis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
  • Candidiasis - Pipeline by Nanomerics Ltd, H2 2016
  • Candidiasis - Pipeline by Novabiotics Limited, H2 2016
  • Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016
  • Candidiasis - Pipeline by Onxeo SA, H2 2016
  • Candidiasis - Pipeline by Scynexis, Inc., H2 2016
  • Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2016
  • Candidiasis - Pipeline by TGV-Laboratories, H2 2016
  • Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016
  • Candidiasis - Pipeline by Wellstat Vaccines, LLC, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Candidiasis - Dormant Projects, H2 2016
  • Candidiasis - Dormant Projects (Contd..1), H2 2016
  • Candidiasis - Dormant Projects (Contd..2), H2 2016
  • Candidiasis - Dormant Projects (Contd..3), H2 2016
  • Candidiasis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Candidiasis, H2 2016
  • Number of Products under Development for Candidiasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top